Nath Bio-Genes Q1 FY27: Board to approve results July 29

Board meeting scheduled for July 29, 2026

Nath Bio-Genes (India) Ltd has informed that its Board of Directors will convene on July 29, 2026. The key agenda item is the consideration and approval of the company’s unaudited financial results for the quarter ended June 30, 2026. The company said the board will take the results “on record” for both standalone and consolidated financials. For listed companies, this board meeting is the formal step that precedes a public financial results announcement to exchanges. The update also sets the immediate timeline for investors tracking the company during the Q1 FY27 results season. Nath Bio-Genes is described as an agri-tech company developing and supplying BT, hybrid, and varietal seeds.

What the company said about the trading window

Alongside the board meeting intimation, Nath Bio-Genes stated that its trading window has been closed from June 30, 2026. It will reopen on August 1, 2026, which the company noted is 48 hours after the declaration of the financial results, in line with insider trading regulations. The notice also indicates the window will be shut from July 1, 2026 until 48 hours after the results are declared for the quarter ending June 30, 2026. Such trading window closures are standard compliance measures under insider trading norms, restricting trading by designated persons during sensitive periods. For market participants, the dates provide clarity on when insider-restricted trading resumes. The timeline also helps narrow the likely disclosure window around the board meeting.

Where the results fit in the broader July-August reporting window

The note indicates results for the quarter ended June 2026 are expected in the July-August 2026 period. That aligns with the broader NSE and BSE reporting cycle for June quarter earnings. While the board meeting date is fixed as July 29, the company’s communication frames the broader “July-August 2026” window as indicative. Investors typically watch for the exchange filing immediately following board approval. Because the trading window reopening date is specified as August 1, 2026, the market has an additional marker linked to the results declaration timeline.

Stock reference points cited in the note

The information provided includes multiple price references for Nath Bio-Genes shares. The company is cited as entering the Q1 FY27 results season trading at around Rs.162 (CMP). Separately, a “Current Share Price” of Rs.172.20 is also listed in the data provided. These references are useful as context for how the stock is positioned heading into the results event, but they are not presented as intraday moves or a specific session close. A 12-month target range of Rs.149-170 is also mentioned as an “Uniresearch estimate,” with the narrative characterising it as a tracking stance. The company’s market capitalisation is shown as Rs.3.27 billion, which equals Rs.327 crore.

Q1 FY27 preview estimates cited (revenue and PAT)

The provided preview data includes a range estimate for Q1 FY27 revenue and net profit (PAT). It cites an expected revenue range of Rs.257-295 crore and a PAT estimate of Rs.16-21 crore. The same table compares this with Q1 FY26 actual revenue of Rs.285 crore and net profit of Rs.37 crore, implying a year-on-year decline in PAT based on those reference numbers. The narrative states the preview is built on a “trailing-growth framework” applied to the Q1 FY26 base, using the most recent year-on-year growth signal from Q4 FY26. The note also states that Q4 FY26 showed revenue of Rs.54 crore and net profit of Rs.0 crore, which it uses as the base for the estimate framework described.

Key numbers table: dates, estimates, and targets

Q1 FY27 estimate range vs Q1 FY26 actuals

The estimate table in the provided material lays out a revenue and PAT range for Q1 FY27 and compares it with Q1 FY26 actuals. It also includes an indicative results date and the same target range repeated across columns. Based on the figures presented, the revenue estimate range of Rs.257-295 crore is placed against Q1 FY26 revenue of Rs.285 crore. For profitability, the PAT range of Rs.16-21 crore is compared with Q1 FY26 net profit of Rs.37 crore.

Operational growth commentary cited for FY27

The material also includes operational pointers around volumes and broader FY27 growth expectations. Cotton volume is expected to grow around 20%, described as consistent with 22% growth achieved in FY26. It further states revenue growth for FY27 is expected between 15-20%, driven by strong volume growth in cotton (22%), paddy (25%), and maize (54%). Separately, it reiterates that overall top-line growth for FY27 is conservatively projected between 15-20%. These points are presented as expectations rather than company guidance in the text provided, and no order book or pending order values are disclosed.

Recent quarterly performance snapshots included in the data

The supplied dataset includes quarterly financial snapshots that provide context going into the Q1 FY27 board meeting. For the quarter ended March 2026, it cites consolidated net sales of Rs.51.59 crore, down 0.72% from Rs.51.97 crore in March 2025. It also mentions a quarterly net loss of Rs.0.01 crore in March 2026 compared with a profit of Rs.1.48 crore in March 2025, and EBITDA of Rs.6.86 crore in March 2026 versus Rs.4.27 crore in March 2025. Another snapshot for “Q4 FY25-26” references revenue of Rs.51 crore and net profit of Rs.0 crore. These figures are presented as reported quarterly numbers, forming part of the context cited for the trailing framework described in the preview.

Company information included in the notice

The text includes the company’s address and contact details as part of the disclosure footprint. The address listed is Nath House, Nath Road, Aurangabad, Maharashtra 431005. It also provides phone numbers (0240-3502421-25), a fax number (0240-2376188), and an investor email (investor@nathbiogenes.com). Such details are typical in corporate filings and help investors and analysts route queries to the investor relations contact. While not directly linked to results performance, these details are part of the company’s standard disclosure set.

Why this event matters for investors tracking Q1 FY27

A scheduled board meeting to approve unaudited quarterly results is a key trigger point for near-term information flow. For Nath Bio-Genes, the July 29 date sets expectations on when the June quarter numbers may be formally approved and disclosed. The trading window closure and the stated reopening on August 1 provide a compliance-linked anchor around the results announcement timeline. The preview numbers and target range cited in the material create a reference frame that some market participants may track against the actual reported results when published. The company has not disclosed any order book or pending order figures in the provided text, keeping the focus primarily on financial reporting and the estimate framework.

Conclusion

Nath Bio-Genes (India) will hold a board meeting on July 29, 2026 to consider and approve its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The trading window is stated to reopen on August 1, 2026, 48 hours after the results declaration. Investors tracking the stock will watch for the exchange filing following the board meeting, and for how the reported revenue and PAT compare with the Q1 FY27 ranges cited in the preview data.